E-MTAB-3606 - Screening of rheumatoid arthritis patients sera against citrullinated fibrinogen peptides using ImmunoCAP ISAC system
Submitted on 7 October 2014, released on 25 October 2015, last updated on 22 February 2016
Citrullinated and unmodified peptides (>95% purity, ProImmune AB) were immobilized onto a chemically modified glass slide, sera from RA patients and healthy controls were applied into the reactions sites and fluorescence intensity after incubation with anti-human IgG antibody was acquired in a laser scanner. Final results for each citrullinated peptide were calculated by subtracting the intensity values of corresponding arginine containing control peptide from citrullinated peptide for all RA patients and controls.
antigen profiling, case control design